Type 1 IFN Function and Signaling in Immunity to Viruses

1 型干扰素在病毒免疫中的功能和信号传导

基本信息

  • 批准号:
    7682782
  • 负责人:
  • 金额:
    $ 39.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-15 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

The type 1 interferons (IFNs), including the IFNs alpha and beta, have potent antiviral effects, but also mediate a wide range of immunoregulatory functions. These include better-characterized effects on NK cells and incompletely understood effects on CD8 T cells. Some are paradoxical, and the mechanisms controlling type 1 IFN effects, to allow access to subsets when needed, are poorly characterized. The cytokines do stimulate a signaling pathway, depending on the signal transducers and activators of transcription (STAT) 1 and 2, to induce direct antiviral effects, but they can conditionally activate all of the STATs, including STAT4, and STAT4 contributes to IFN-? induction. As a result of experiments demonstrating that total STAT1 protein is dramatically induced at early times after infection, and that type 1 IFN activation of STAT4 negatively correlates with STAT1 levels, this project proposed to test the hypotheses that type 1 IFN effects are controlled by regulation of access to different intracellular signaling pathways, and that this regulation is required and delivered during innate and adaptive immune responses to viral infections. The work has proven the hypotheses to be correct. Unexpected mechanisms for the delivery of access to STAT1 as compared to STAT4 were discovered at the levels of differential expression of STAT4 and of apparent competition for binding to the type 1 IFN receptor, and these were shown to be important for health. Experiments are proposed in this renewal application to test the hypotheses that STATs act as master switches in promoting cellular responses by both enhancing and inhibiting type 1 IFN effects, and that the STAT1 and STAT4 effects on the reciprocal signaling pathway are influenced by, and have consequences for, other STAT molecules. This will be accomplished through four specific aims focusing on NK and CD8 T cell responses. Aim 1 will define the use of STATs as master switches to mediate positive and negative effects on responsiveness to type 1 IFNs. Aim 2 will mechanistically define the pathways regulating STAT levels. Aim 3 will broaden the characterization of type 1 IFN access to other STATs. Aim 4 will define the importance of modulating STAT levels and access for delivery of changing type 1 IFN biological functions during viral infection. Immunological, virological, biochemical, and molecular techniques will be used, and the work will be advanced by studies of responses ex vivo following exposure to cytokines, and in vivo following lymphocytic choriomeningitis virus infections in wild type and genetically altered mice. The project promises to continue to advance understanding of the control of type 1 IFN effects in shaping immune responses to infection, and to provide insights for use of cytokines in therapeutic applications. Even more broadly, however, it will identify paradigms for how cytokine effects are regulated to add value to a limited number of genes.
1型干扰素(IFN),包括IFNα和β,具有强大的抗病毒作用,但也 调节广泛的免疫调节功能。这些包括更具特征性的影响 NK细胞和对CD8T细胞的作用还不完全清楚。有些是自相矛盾的,而 控制1型干扰素效应以允许在需要时访问子集的机制很差 特色化的。细胞因子确实会刺激信号通路,这取决于信号转导。 和转录激活因子(STAT)1和2,以诱导直接的抗病毒作用,但它们可以 有条件地激活所有的统计数据,包括STAT4,STAT4有助于干扰素??归纳法。 由于实验表明,总的STAT1蛋白在早期被显著诱导 STAT4的1型干扰素活性与STAT1水平呈负相关, 该项目旨在验证1型干扰素效应受调控的假说。 获得不同的细胞内信号通路,并且这一调节是必需的并被提供 在对病毒感染的先天和获得性免疫反应过程中。这项工作证明了 假设是正确的。与之相比,提供对STAT1的访问的意外机制 TO STAT4在STAT4的差异表达水平和表观表达水平上被发现 竞争与1型干扰素受体的结合,这些被证明对健康很重要。 在这个更新的应用程序中提出了一些实验,以检验统计数据充当主控的假设 通过增强和抑制1型干扰素效应来促进细胞反应的开关,以及 STAT1和STAT4在相互信号通路上的作用受其影响,并具有 对其他状态分子的影响。这将通过四个具体目标来实现 重点关注NK和CD8 T细胞反应。目标1将定义统计信息的使用作为主开关,以 调节对1型干扰素反应的积极和消极影响。目标2将机械地 定义调节状态水平的路径。目标3将拓宽1型干扰素的特征 获取其他统计数据。目标4将定义调制统计信息级别和接入的重要性 病毒感染期间1型干扰素生物学功能的改变。免疫学,病毒学, 将使用生化和分子技术,并将通过研究 接触细胞因子后的体外反应和淋巴细胞性脉络膜脑膜炎后的体内反应 野生型和转基因小鼠的病毒感染。该项目有望继续向前推进。 了解控制1型干扰素在形成对感染的免疫反应中的作用,并 为细胞因子在治疗应用中的使用提供见解。然而,更广泛地说,它将 确定如何调节细胞因子效应以增加有限数量基因的价值的范例。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTINE A. BIRON其他文献

CHRISTINE A. BIRON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTINE A. BIRON', 18)}}的其他基金

NK Cell STAT3 and Virus-induced IL-6 Disease
NK 细胞 STAT3 和病毒诱导的 IL-6 疾病
  • 批准号:
    9352931
  • 财政年份:
    2016
  • 资助金额:
    $ 39.75万
  • 项目类别:
EVENTS REGULATING THE BALANCE BETWEEN RESISTANCE & INFECTION
调节阻力平衡的事件
  • 批准号:
    7170316
  • 财政年份:
    2005
  • 资助金额:
    $ 39.75万
  • 项目类别:
EVENTS REGULATING THE BALANCE BETWEEN RESISTANCE & INFECTION
调节阻力平衡的事件
  • 批准号:
    7011753
  • 财政年份:
    2004
  • 资助金额:
    $ 39.75万
  • 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
  • 批准号:
    6671292
  • 财政年份:
    2003
  • 资助金额:
    $ 39.75万
  • 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
  • 批准号:
    8309406
  • 财政年份:
    2003
  • 资助金额:
    $ 39.75万
  • 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
  • 批准号:
    6758522
  • 财政年份:
    2003
  • 资助金额:
    $ 39.75万
  • 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
  • 批准号:
    7148056
  • 财政年份:
    2003
  • 资助金额:
    $ 39.75万
  • 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
  • 批准号:
    8112698
  • 财政年份:
    2003
  • 资助金额:
    $ 39.75万
  • 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
  • 批准号:
    7787580
  • 财政年份:
    2003
  • 资助金额:
    $ 39.75万
  • 项目类别:
Type 1 IFN Function and Signaling in Immunity to Viruses
1 型干扰素在病毒免疫中的功能和信号传导
  • 批准号:
    6824915
  • 财政年份:
    2003
  • 资助金额:
    $ 39.75万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 39.75万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 39.75万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 39.75万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 39.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了